Nuvation Bio annual stock-based compensation
2020
2021
2022
2023
2024
2025
Nuvation Bio Stock-Based Compensation Growth & History (NUVB)
Nuvation Bio's stock-based compensation was $35.9M for fiscal 2025.
View full Nuvation Bio company overviewNuvation Bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $35.9M | $3.6M | +11.21% |
| 2024 | 2024-12-31 | $32.3M | $12.8M | +65.40% |
| 2023 | 2023-12-31 | $19.5M | $3.2M | +19.77% |
| 2022 | 2022-12-31 | $16.3M | $7.0M | +75.79% |
| 2021 | 2021-12-31 | $9.3M | $7.1M | +320.89% |
| 2020 | 2020-12-31 | $2.2M | — | — |
Nuvation Bio quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.5M | −$1.6M | −13.06% |
| Q1 2026 | 2026-03-31 | $9.0M | $1.2M | +15.01% |
| Q4 2025 | 2025-12-31 | $8.0M | −$2.2M | −21.60% |
| Q3 2025 | 2025-09-30 | $8.0M | $545,000 | +7.29% |
| Q2 2025 | 2025-06-30 | $12.0M | $2.5M | +25.73% |
| Q1 2025 | 2025-03-31 | $7.9M | $2.8M | +55.80% |
| Q4 2024 | 2024-12-31 | $10.2M | $6.5M | +173.75% |
| Q3 2024 | 2024-09-30 | $7.5M | $2.0M | +37.65% |
| Q2 2024 | 2024-06-30 | $9.6M | $4.0M | +73.26% |
| Q1 2024 | 2024-03-31 | $5.0M | $204,000 | +4.22% |
| Q4 2023 | 2023-12-31 | $3.7M | −$1.3M | −25.38% |
| Q3 2023 | 2023-09-30 | $5.4M | $2.5M | +84.73% |
| Q2 2023 | 2023-06-30 | $5.5M | $736,000 | +15.37% |
| Q1 2023 | 2023-03-31 | $4.8M | $1.3M | +35.23% |
| Q4 2022 | 2022-12-31 | $5.0M | $2.2M | +78.14% |
| Q3 2022 | 2022-09-30 | $2.9M | $191,000 | +6.95% |
| Q2 2022 | 2022-06-30 | $4.8M | $2.6M | +122.34% |
| Q1 2022 | 2022-03-31 | $3.6M | $2.0M | +128.42% |
| Q4 2021 | 2021-12-31 | $2.8M | $1.7M | +148.89% |
| Q3 2021 | 2021-09-30 | $2.7M | $2.4M | +689.94% |
| Q2 2021 | 2021-06-30 | $2.2M | $1.8M | +453.47% |
| Q1 2021 | 2021-03-31 | $1.6M | $1.2M | +360.59% |
| Q4 2020 | 2020-12-31 | $1.1M | — | — |
| Q3 2020 | 2020-09-30 | $348,000 | — | — |
| Q2 2020 | 2020-06-30 | $389,000 | — | — |
| Q1 2020 | 2020-03-31 | $340,000 | — | — |
Nuvation Bio stock-based compensation trends
Over the last five fiscal years, Nuvation Bio's stock-based compensation increased from $2.2M to $35.9M, a change of $33.7M. The latest reported quarter, Q2 2026, shows $10.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvation Bio source filings ↗